Innovations in Technology
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Innovations in Technology
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
Recent innovations in addiction treatment technology are transforming clinical care. These advancements provide novel, personalized treatment options, facilitate real-time communication with healthcare providers, and promote engagement in recovery and harm reduction. This session will discuss new approaches such as tele-harm reduction, brain stimulation, and more.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Harnessing Digital Health in the Assessment and Treatment of Substance Use Disorders
This session explores the role of digital health technologies in the assessment and treatment of substance use disorders. Attendees will learn about innovative digital tools that enhance screening accuracy, personalize treatment, and improve patient engagement. The discussion will cover the benefits, challenges, and ethical considerations of using digital health in clinical practice, as well as its potential to transform substance use care.
- Tele-Harm Reduction
This session will introduce Tele-Harm Reduction (THR) as a crucial and innovative tool towards ending the HIV epidemic. THR leverages telehealth technology to deliver comprehensive care within syringe services programs (SSPs). T-SHARP is a clinical trial that aims to improve HIV outcomes among people who inject drugs (PWID). The trial evaluates the efficacy of this telehealth intervention in achieving viral suppression, initiating medications for opioid use disorder (MOUD), and curing hepatitis C. By bridging the digital divide and meeting PWID where they are, T-SHARP seeks to transform HIV care delivery and improve clinical outcomes. - Randomized Repetitive Transcranial Magnetic Stimulation Trial for Smoking Cessation
A comparison of 1 Hz rTMS over the medial frontal cortex and 10 Hz rTMS over the dorsolateral prefrontal cortex was completed in healthy smokers. Results showed that 10 Hz rTMS reduced cigarette consumption more than 1 Hz rTMS as well as sham TMS. 10 Hz treatment increased brain activity in the lateral prefrontal cortex and decreased brain activity in the medial frontal cortex. The study demonstrates that 10 Hz rTMS stimulation of the dorsolateral prefrontal cortex in an executive control circuit may be better for developing brain stimulation treatment than 1Hz rTMS of the medial orbitofrontal cortex in a medial reward circuit. - Primary and Secondary Findings from the NIDA CTN ADAPT-2 Trial in Relation to the Treatment of Methamphetamine Use Disorder
This session will delve into the cutting-edge research and treatment options for stimulant use disorders. Participants will learn about the latest pharmacotherapy developments and the significance of biomarker research in enhancing treatment efficacy. The discussion will also cover the challenges faced in treating stimulant use disorders and propose innovative solutions. Overall, the session aims to provide a comprehensive understanding of the evolving landscape of stimulant use disorder treatments.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Madhukar H. Trivedi
MD
Madhukar Trivedi is Professor of Psychiatry, Chief of the Division of Mood Disorders, and Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. He earned his MBBS and MS in Baroda, India, completing his residencies in Psychiatry at University General Hospital, Baroda, India and Henry Ford Hospital, Detroit, Michigan. He completed his fellowship at UT Southwestern, where he now serves as Betty Jo Hay Distinguished Chair in Mental Health and Julie K. Hersh Chair for Depression Research and Clinical Care. Certified by the American Board of Psychiatry and Neurology, Dr. Trivedi is an established clinical and translational researcher with extensive experience serving as PI and Co-PI on several single and multi-site clinical trials funded by NIH, foundations and industry sponsors.
Dr. Trivedi’s research over the last 25 years has focused on understanding the neurobiology and psychology of depression and bipolar disorder, with a particular focus on developing an empirical basis for improving treatment of depression. Dr. Trivedi and his team have been involved in many of the pivotal studies involving the establishment of efficacy of antidepressant treatments (medications, psychotherapy, exercise, complimentary treatments, devices, etc.), examining next steps in treatment resistant depression to develop algorithms and guidelines, and developing and validating biomarkers in order to reach the goal of precision medicine for mood disorders. Among his most notable studies are the Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, Combining Medications to Enhance Depression Outcomes (CO-MED) trial, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and the Texas Resilience Against Depression (T-RAD) study.
Does Disclose: Alkermes; monetary payment; Consulting Alto Neuroscience Inc; monetary payment & stock investments; Stockholder / Scientific Advisory Axsome Therapeutics, Inc.; N/A; Consulting Biogen MA Inc; monetary payment; Consulting Circular Genomics Inc.; stock investments; Consulting / Stockholder GH Research Limited; monetary payment; Consulting GreenLight VitalSign6; stock investments; Stockholder / Scientific Advisory Heading Health, Inc; n/a; Scientific Advisory; Janssen; n/a; Consulting Legion Health; stock investment; Stockholder / Scientific Advisory Mind Medicine (MindMed) Inc.; n/a; Consulting Neurocrine Biosciences Inc; n/a; Consulting Orexo US Inc; monetary payment; Consulting / Scientific Advisory Otsuka America Pharmaceutical, Inc.; monetary payment; Consulting Otsuka Canada Pharmaceutical Inc; monetary payment; Consulting Otsuka Pharmaceutical Development & Commercialization, Inc.; monetary payment; Consulting; Sage Therapeutics; monetary payment; Consulting Takeda Pharmaceutical Company Ltd.; n/a; Consutling WebMD; monetary payment; Consulting Sparian Biosciences; n/a; Consulting
Dr. Lisa Marsch, PhD
Professor of Psychiatry, Center for Technology and Behavioral Health; Geisel School of Medicine at Dartmouth College
Lisa A. Marsch, PhD is the Director of the Center for Technology and Behavioral Health (a NIDA-funded P30 Center of Excellence) at Dartmouth College. With funding from NIH, she has led a line of research focused on the development and evaluation of cutting-edge, technology-based (mobile and Internet-delivered) interventions focused on substance abuse treatment among youth and adults, HIV prevention among substance-using youth and adults, substance abuse prevention among children and adolescents, as well as other behavioral health issues.
These technology-based therapeutic tools reflect an integration of science-based behavioral interventions with evidence-based informational technologies. This work has been conducted in a variety of settings, including physician offices, substance abuse treatment programs, criminal justice settings, primary care settings, educational settings and via the Internet.
Teresa A. Chueng, MD, MPH
Assistant Professor of Clinical Medicine
University of Miami Miller School of Medicine
Dr. Teresa Chueng is a public health physician trained in internal medicine and infectious disease; she joined University of Miami Miller School of Medicine as an Assistant Professor of Clinical Medicine in 2022.
Dr. Chueng is passionate about the intersection of infectious diseases with addiction medicine. She is faculty at the IDEA Exchange, Florida's first syringe services program where she provides low-barrier care to people with substance use disorder. She is also Associate Director of the Severe Injection Related Infections (SIRI) Team at Jackson Memorial Hospital, an inpatient infectious disease and addiction consultation service that offers integrated and holistic care for people who use drugs. She co-leads the women's clinic at IDEA Exchange to provide medications for substance use disorder, wound care, contraception, and sexually transmitted infection treatment. Dr. Chueng also is a core faculty member in the Department of Medicine, where she co-runs the addiction medicine rotation to train the next generation of internal medicine residents.
No relevant financial disclosures
Xingbao Li, MD, MS
Associate Professor
Medical University of South Carolina
Dr. Li earned his M.D. and M.S. in China. In 2019, Dr. Li completed his Master of Science in Clinical Research at the Medical University of South Carolina (MUSC). He has been working in the Brain Stimulation Lab since 2000. He is also a faculty member at the Center for Biomedical Imaging (CBI) at MUSC. His research interests include transcranial magnetic stimulation (TMS), functional MRI, and combining TMS and functional MRI techniques in neuropsychiatry, especially in substance abuse. Dr. Li is a pioneer in using TMS for smoking cessation. US NIH has awarded Dr. Li in the development of addiction therapy since 2014. Now, Dr. Li is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at MUSC.
No relevant financial disclosures
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 1.75 Credit(s)
- Nurses & NPs: 1.75 Nursing Contact Hour(s)
- Pharmacology Hour(s): 0.5 Hour(s)
- PAs: 1.75 Credit(s)
- Pharmacists: 1.75 Credit(s)
- Interprofessional Continuing Education: 1.75 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 1.75 Lifelong Learning
- ABIM MOC Points: 1.75 Medical Knowledge
- ABP MOC: 1.75 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 1.75 Accredited CME | 1.75 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked